옵션 체인은 다양한 행사가격과 만기일에 대한 10x Genomics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 10x Genomics에 대한 시장 심리를 평가합니다..

10x Genomics (NASDAQ:TXG) 주식, 옵션 체인

10x Genomics

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ETFs

ADPT

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NRIX

NTRA

PATH

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

Equities

News

Markets

ARKW

BEAM

GTLB

목요일, 캐시 우드의 아크 인베스트(Ark Invest)가 자율주행 택시 부문에서 테슬라(NASDAQ:TSLA)의 잠재력에 대한 최근 낙관적인 전망에도 불구하고 이 회사의 지분을 축소하는 중요한 움직임을 보였다.

캐시 우드의 아크 인베스트는 긍정적인 자율주행 전망에도 $800만 테슬라 주식 매도

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

NTLA

TDOC

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 변동성이 큰 시장 속에서 로쿠(NASDAQ:ROKU)와 코인베이스 글로벌(NASDAQ:COIN)에서 상당한 거래를 했다. 이러한 눈에 띄는 거래는 아크의 다양한 ETF가 수행한 일련의 거래의 일부였다.
로쿠 거래

아크 인베스트는 로쿠 $730만의 주식을 매수, 비트코인 하락에 코인베이스 주식을 매각

10x Genomics Inc

TEXAS GULF ENERGY INC by Texas Gulf Energy, Incorporated.

Texas Gulf Energy Inc

S&P/TSX GlbMn US

S&P/TSX Global Gold Index (USD)

S&P/TSX Global Gold Index (USD) (TR)

HeartCore Enterprises, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) ("HeartCore" or "the Company"), a leading enterprise software and data consulting services company based in Tokyo, announced today that it has received written notice from the Nasdaq Stock Market LLC that the Company demonstrated compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") and that the Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the Company's securities will continue to be listed and traded on The Nasdaq Stock Market.

HTCR

HeartCore Regains Compliance With Nasdaq Listing Requirements

WIIM

EOSE

Eos Energy Enterprises shares are trading lower after the company reported Q3 financial results and cut its FY24 revenue guidance.

Blend (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>), the leading origination platform for digital banking solutions, and Covered Insurance Solutions (Covered), a premier provider of embedded insurance solutions, have announced a new strategic partnership to further streamline the home insurance shopping experience.

BLND

Blend And Covered Insurance Announce New Strategic Partnership To Streamline Home Insurance Shopping

She succeeds Robert Wood, previous Chairman of the Board, who has retired from the board for personal reasons.&nbsp;

Management

MRC Global Names Deborah Adams As Its New Board Chair, Effective Immediately

Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) affirms FY2026 sales outlook from $1.52 billion-1.77 billion to $1.52 billion-1.77 billion.

Guidance

VTOL

Bristow Group Affirms FY2026 Sales Guidance from $1.52B-1.77B to $1.52B-1.77B

Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) affirms FY2025 sales outlook from $1.44 billion-1.61 billion to $1.44 billion-1.61 billion.

Bristow Group Affirms FY2025 Sales Guidance from $1.44B-1.61B to $1.44B-1.61B

CYTK

Cytek Biosciences shares are trading higher following better-than-expected Q3 earnings.

Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) narrows FY2024 sales outlook from $1.35 billion-1.42 billion to $1.35 billion-1.41 billion.

Bristow Group Narrows FY2024 Sales Guidance from $1.35B-1.42B to $1.35B-1.41B

Arteris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIP#NASDAQ">AIP</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 33.33 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $14.71 million which met the analyst consensus estimate. This is a 10.84 percent increase over sales of $13.27 million the same period last year.

Earnings

Earnings Beats

Arteris Q3 Adj $(0.08) Beats $(0.12) Estimate, Sales $14.71M Inline

Safety Insurance Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFT#NASDAQ">SAFT</a>) reported quarterly earnings of $1.10 per share which missed the analyst consensus estimate of $1.40 by 21.43 percent. This is a 86.44 percent increase over earnings of $0.59 per share from the same period last year. The company reported $295.28 million in sales this quarter. This is a 28.74 percent increase over sales of $229.36 million the same period last year.

Earnings Misses

SAFT

Safety Insurance Group Q3 EPS $1.10 Misses $1.40 Estimate, Sales $295.28M Up From $229.36M YoY

Select Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTTR#NYSE">WTTR</a>) reported quarterly earnings of $0.15 per share which met the analyst consensus estimate. The company reported quarterly sales of $371.349 million which beat the analyst consensus estimate of $350.908 million by 5.83 percent. This is a 4.60 percent decrease over sales of $389.273 million the same period last year.

WTTR

Select Water Solutions Q3 2024 GAAP EPS $0.15, Inline, Sales $371.349M Beat $350.908M Estimate

Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) reported quarterly earnings of $0.21 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $135.392 million which missed the analyst consensus estimate of $157.606 million by 14.09 percent. This is a 14.43 percent decrease over sales of $158.217 million the same period last year.

Mayville Engineering Q3 2024 Adj. EPS $0.21, Inline, Sales $135.392M Miss $157.606M Estimate

LoanDepot shares are trading higher after the company reported better-than-expected Q3 financial results.

Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) raises FY2024 sales outlook from $515.00 million-535.00 million to $520.00 million-540.00 million.

Limbach Holdings Raises FY2024 Sales Guidance from $515.00M-535.00M to $520.00M-540.00M  VS Est. 519.25M

UFCS

United Fire Group shares are trading higher after the company reported better-than-expected Q3 financial results.

BBAI

BigBear.ai shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.54 by 9.26 percent. This is a 34.09 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $194.500 million which missed the analyst consensus estimate of $196.574 million by 1.06 percent. This is a 3.43 percent decrease over sales of $201.400 million the same period last year.

HLIO

Helios Technologies Q3 2024 Adj. EPS $0.59 Beats $0.54 Estimate, Sales $194.500M Miss $196.574M Estimate

2024 ANNUAL GUIDANCE(1)
NOG is reiterating capital expenditure and production guidance and adjusting certain line items. Production taxes are being adjusted to reflect current expectations for the remainder of the year. Natural gas realizations and oil differentials are being adjusted to reflect results experienced year-to-date. Per unit cash G&amp;A is being lowered as the Company has reduced certain external expenses and continues to benefit from increasing production volumes.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Prior Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revised Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Annual Production (Boe per day)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">120,000 - 124,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">120,000 - 124,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Annual Oil Production (Bbls per day)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73,000 - 76,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73,000 - 76,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Capital Expenditures ($ in millions)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890 - $970</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890 - $970</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Wells Turned-in-Line ("TIL")</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">93.0 - 98.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">93.0 - 98.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Wells Spud</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73.0 - 78.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73.0 - 78.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Expenses and Differentials:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production Expenses (per Boe)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.15 - $9.40</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.15 - $9.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production Taxes (as a percentage of Oil &amp; Gas Sales)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">9.0% - 9.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">8.5% - 9.0%(2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Differential to NYMEX WTI (per Bbl)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($4.00) - ($4.85)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($4.00) - ($4.50)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Realization as a Percentage of NYMEX Henry Hub (per Mcf)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">87.5% - 92.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">90.0% - 95.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">DD&amp;A Rate (per Boe)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$16.50 - $17.50</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$16.50 - $17.50</td>
</tr>
</tbody>
</table>
</figure>

NOG Reiterates Capital Expenditure And Production Guidance

loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.04) by 150 percent. The company reported quarterly sales of $314.598 million which beat the analyst consensus estimate of $275.995 million by 13.99 percent. This is a 18.42 percent increase over sales of $265.661 million the same period last year.

loanDepot Q3 2024 Adj. EPS $0.02 Beats $(0.04) Estimate, Sales $314.598M Beat $275.995M Estimate

SWIM

Latham Group shares are trading lower after the company reported worse-than-expected Q3 financial results and narrowed its FY24 sales guidance.

Analyst Daniel Brennan of TD Cowen maintained a Hold rating on 10x Genomics (TXG – Research Report), retaining the price target of $18.00. Daniel B...

10x Genomics: Balancing Market Challenges and Strategic Opportunities

In a report released yesterday, Patrick B Donnelly from Citi maintained a Buy rating on 10x Genomics (TXG – Research Report), with a price target o...

Resilient Growth Prospects Amid Challenges: Patrick B Donnelly's Buy Rating on 10x Genomics

10x Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Puneet Souda from Le...

10x Genomics: Buy Rating Amid Short-term Disruptions and Long-term Growth Prospects

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report). The co...

Bank of America Securities Sticks to Its Hold Rating for 10x Genomics (TXG)

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on 10x Genomics (TXG – Research Report) yesterday and set a price target of $21.00. Th...

Stifel Nicolaus Remains a Buy on 10x Genomics (TXG)

Analyst Tejas Savant of Morgan Stanley maintained a Buy rating on 10x Genomics (TXG – Research Report), reducing the price target to $30.00. Tejas ...

Buy Rating on 10x Genomics: Strategic Restructuring and Long-term Growth Prospects

10X Genomics (TXG) has disclosed a new risk, in the Environmental / Social category. In a noteworthy development for 10X Genomics, CEO Serge Saxono...

10X Genomics CEO Serge Saxonov Initiates Rule 10b5-1 Trading Plan Amid Strategic Financial Maneuvering

10x Genomics (TXG) and French TechBio startup Cure51 announced that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to un...

10x Genomics' Visium HD selected by TechBio startup Cure51

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report), 10x Genomics (TXG –...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), 10x Genomics (TXG) and Bicycle Therapeutics (BCYC)

Barclays analyst Luke Sergott lowered the firm's price target on 10x Genomics (TXG) to $19 from $21 and keeps an Overweight rating on the shares. T...

10x Genomics price target lowered to $19 from $21 at Barclays

BCYC

Press Releases

10x Genomics Reports Second Quarter 2024 Financial Results

10x Genomics Announces Senior Leadership Changes

10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research

Lausanne Researchers Combine 10x Genomics' Chromium and Xenium for Novel Insights into Resistance and Potential Therapeutics for Brain Cancer

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting

10x Genomics Announces Preliminary Select Third Quarter 2024 Results

10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches

10x Genomics Reports Third Quarter 2024 Financial Results

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

10x Genomics

10x Genomics (TXG) 옵션

10x Genomics (NASDAQ:TXG) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌